Karyopharm is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation.

The International Vaccines and Virology Conference welcomes you to London, UK during October 14-15, 2021 to share your research findings, promote knowledge exchange and network with a broad audience in the field of microbiology and immunology. i-Vaccines 2021 is an annual gathering for researchers, practitioners, and educators to share the insights and discuss the recent innovations, research, concerns as well as practical challenges encountered, and development to improve healthcare sector's preventive and cure needs. The conference’s global goal is to deliberate and disseminate innovative ideas among academics, research and development executives, scientists, industrialists, and policymakers to deepen the comprehension and transform the knowledge into innovative solutions for patient care. The i-Vaccines Operating Committee invites the submission of abstracts covering a broad range of cross-cutting topics including Vaccines and Gene Therapy, Viral Oncogenesis.